save and improve the lives of patients
learn moreawareness
There is an outstanding need for new treatments for bladder cancer. We are proud to support the Bladder Cancer Advocacy Network in building awareness of the need for a cure.
results
Our preliminary Phase 3 data show Vicinium® is very well-tolerated and with demonstrated efficacy in patients with high-grade NMIBC.
innovation
Vicinium is a targeted fusion protein designed to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates.
bringing new hope for treating bladder cancer
Vicinium is our novel, lead product candidate that we hope will change the treatment landscape for patients with high-grade, non-muscle invasive bladder cancer (NMIBC). To-date, Vicinium has been well-tolerated in treated patients and has demonstrated efficacy, resulting in a 17% complete response rate for patients with 12-month follow-ups in our ongoing Phase 3 trial.
LEARN MORE
BLADDER CANCER
6th
most common cancer
72
average age of diagnosis
80,000+
new cases each year in the U.S.
$4 billion
annual costs
what we’ve been up to
03/16/20
Sesen Bio Reports Fourth Quarter and Full-Year 2019 Financial Results
02/25/20
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®
02/24/20
Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®
RENEW LIFE
change lives with us
We are a group of motivated individuals who are committed to changing lives for the better. Learn more about our open positions and how you can renew life with us.
learn more